Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes

Journal of Immunology

Volumn 179, Issue 2, 2007, Pages 901-909

  Segain, Jean Pierre ^a,b   Rolli Derkinderen, Malvyne ^b,c   Gervois, Nadine ^b,c   De La Blétière, Diane Raingeard ^a,b   Loirand, Gervaise ^b,c,d   Pacaud, Pierre ^b,c  

^a CEMAGREF   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c INSERM   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; UROTENSIN; UTS2R PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BINDING SITE; CELL STIMULATION; CHEMOTAXIS; CONTROLLED STUDY; CYTOSKELETON; ENZYME ACTIVATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOLECULAR CLONING; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPLEEN CELL; T LYMPHOCYTE; UT RECEPTOR GENE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; NEUTROPHIL CHEMOTAXIS; NUCLEOTIDE SEQUENCE; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS;

ACTINS; ANIMALS; B-LYMPHOCYTES; BASE SEQUENCE; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; CLONING, MOLECULAR; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; KILLER CELLS, NATURAL; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR SEQUENCE DATA; MONOCYTES; MUTAGENESIS, SITE-DIRECTED; NF-KAPPA B; PROMOTER REGIONS (GENETICS); RATS; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHOA GTP-BINDING PROTEIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION; UROTENSINS;

EID: 34548770184     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.2.901     Document Type: Article

References (53)

1. Straub, R. H., J. Westermann, J. Scholmerich, and W. Falk. 1998. Dialogue between the CNS and the immune system in lymphoid organs. Immunol. Today 19: 409-413.
2. Frieri, M. 2003. Neuroimmunology and inflammation: implications for therapy of allergic and autoimmune diseases. Ann. Allergy Asthma Immunol. 90: 34-40.
3. Lotz, M., J. H. Vaughan, and D. A. Carson. 1988. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 241: 1218-1221.
4. Makarenkova, V. P., G. V. Shurin, I. L. Tourkova, L. Balkir, G. Pirtskhalaishvili, L. Perez, V. Gerein, J. M. Siegfried, and M. R. Shurin. 2003. Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells. J. Neuroimmunol. 145: 55-67.
5. Delgado, M., and D. Ganea. 2001. Cutting edge: is vasoactive intestinal peptide a type 2 cytokine. J. Immunol. 166: 2907-2912.
6. Dunzendorfer, S., A. Kaser, C. Meierhofer, H. Tilg, and C. J. Wiedermann. 2001. Cutting edge: peripheral neuropeptides attract immature and arrest mature blood-derived dendritic cells. J. Immunol. 166: 2167-2172.
7. Serhan, C. N., I. M. Fierro, N. Chiang, and M. Pouliot. 2001. Cutting edge: nociceptin stimulates neutrophil chemotaxis and recruitment: inhibition by aspirin-triggered-15-epi-lipoxin A4. J. Immunol. 166: 3650-3654.
8. Hokfelt, T., T. Bartfai, and F. Bloom. 2003. Neuropeptides: opportunities for drug discovery. Lancet Neurol. 2: 463-472.
9. Maguire, J. J., and A. P. Davenport. 2002. Is urotensin-II the new endothelin. Br. J. Pharmacol. 137: 579-588.
10. Ames, R. S., H. M. Sarau, J. K. Chambers, R. N. Willette, N. V. Aiyar, A. M. Romanic, C. S. Louden, J. J. Foley, C. F. Sauermelch, R. W. Coatney, et al. 1999. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401: 282-286.
11. Coulouarn, Y., I. Lihrmann, S. Jegou, Y. Anouar, H. Tostivint, J. C. Beauvillain, J. M. Conlon, H. A. Bern, and H. Vaudry. 1998. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc. Natl. Acad. Sci. USA 95: 15803-15808.
12. Maguire, J. J., R. E. Kuc, and A. P. Davenport. 2000. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br. J. Pharmacol. 131: 441-446.
13. Douglas, S. A., A. C. Sulpizio, V. Piercy, H. M. Sarau, R. S. Ames, N. V. Aiyar, E. H. Ohlstein, and R. N. Willette. 2000. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br. J. Pharmacol. 131: 1262-1274.
14. Matsushita, M., M. Shichiri, T. Imai, M. Iwashina, H. Tanaka, N. Takasu, and Y. Hirata. 2001. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J. Hypertens. 19: 2185-2190.
15. Behm, D. J., S. M. Harrison, Z. Ao, K. Maniscalco, S. J. Pickering, E. V. Grau, T. N. Woods, R. W. Coatney, C. P. Doe, R. N. Willette, et al. 2003. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br. J. Pharmacol. 139: 464-472.
16. Bohm, F., and J. Pernow. 2002. Urotensin II evokes potent vasoconstriction in humans in vivo. Br. J. Pharmacol. 135: 25-27.
17. Camarda, V., A. Rizzi, G. Calo, G. Gendron, S. I. Perron, E. Kostenis, P. Zamboni, F. Mascoli, and D. Regoli. 2002. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn. Schmiedebergs. Arch. Pharmacol. 365: 141-149.
18. MacLean, M. R., D. Alexander, A. Stirrat, M. Gallagher, S. A. Douglas, E. H. Ohlstein, I. Morecroft, and K. Polland. 2000. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br. J. Pharmacol. 130: 201-204.
19. Maguire, J. J., R. E. Kuc, K. E. Wiley, M. J. Kleinz, and A. P. Davenport. 2004. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 25: 1767-1774.
20. Sauzeau, V., E. Le Mellionnec, J. Bertoglio, E. Scalbert, P. Pacaud, and G. Loirand. 2001. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ. Res. 88: 1102-1104.
21. Watanabe, T., R. Pakala, T. Katagiri, and C. R. Benedict. 2001. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 104: 16-18.
22. Hassan, G. S., S. A. Douglas, E. H. Ohlstein, and A. Giaid. 2005. Expression of urotensin-II in human coronary atherosclerosis. Peptides 26: 2464-2472.
23. Bousette, N., L. Patel, S. A. Douglas, E. H. Ohlstein, and A. Giaid. 2004. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176: 117-123.
24. Chatenet, D., C. Dubessy, J. Leprince, C. Boularan, L. Carlier, I. Segalas-Milazzo, L. Guilhaudis, H. Oulyadi, D. Davoust, E. Scalbert, et al. 2004. Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides 25: 1819-1830.
25. Feve, B., J. P. Segain, B. Charbonnel, and P. Sai. 1990. B cell-adherent splenocytes precede the onset of diabetes in low-dose streptozotocin-treated mice. Diabetologia 33: 9-14.
26. -ΔΔCT method. Methods 25: 402-408.
27. Vicente-Manzanares, M., J. R. Cabrero, M. Rey, M. Perez-Martinez, A. Ursa, K. Itoh, and F. Sanchez-Madrid. 2002. A role for the Rho-p160 Rho coiled-coil kinase axis in the chemokine stromal cell-derived factor-1α-induced lymphocyte actomyosin and microtubular organization and chemotaxis. J. Immunol. 168: 400-410.
28. 2+ sensitization of contraction in vascular smooth muscle. J. Biol. Chem. 275: 21722-21729.
29. Ren, X. D., W. B. Kiosses, and M. A. Schwartz. 1999. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J. 18: 578-585.
30. + subpopulation. Immunol. Today 17: 424-428.
31. Lombardi, M. S., A. Kavelaars, and C. J. Heijnen. 2002. Role and modulation of G protein-coupled receptor signaling in inflammatory processes. Crit. Rev. Immunol. 22: 141-163.
32. Scherf, M., A. Klingenhoff, and T. Werner. 2000. Highly specific localization of promoter regions in large genomic sequences by PromoterInspector: a novel context analysis approach. J. Mol. Biol. 297: 599-606.
33. Quandt, K., K. Frech, H. Karas, E. Wingender, and T. Werner. 1995. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 23: 4878-4884.
34. Cartharius, K., K. Frech, K. Grote, B. Klocke, M. Haltmeier, A. Klingenhoff, M. Frisch, M. Bayerlein, and T. Werner. 2005. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21: 2933-2942.
35. Vicente-Manzanares, M., and F. Sanchez-Madrid. 2004. Role of the cytoskeleton during leukocyte responses. Nat. Rev. Immunol. 4: 110-122.
36. Etienne-Manneville, S., and A. Hall. 2002. Rho GTPases in cell biology. Nature 420: 629-635.
37. Fukata, Y., M. Amano, and K. Kaibuchi. 2001. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol. Sci. 22: 32-39.
38. Kimura, K., M. Ito, M. Amano, K. Chihara, Y. Fukata, M. Nakafuku, B. Yamamori, J. Feng, T. Nakano, K. Okawa, et al. 1996. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273: 245-248.
39. Ridley, A. J. 2001. Rho GTPases and cell migration. J. Cell. Sci. 114: 2713-2722.
40. +) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J. Exp. Med. 196: 517-527.s
41. + monocytes in response to sepsis-related antigens. Clin. Exp. Immunol. 141: 270-278.
42. Rothe, G., H. Gabriel, E. Kovacs, J. Klucken, J. Stohr, W. Kindermann, and G. Schmitz. 1996. Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 16: 1437-1447.
43. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340: 115-126.
44. Murphy, P. M. 1994. The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol. 12: 593-633.
45. Allen, W. E., D. Zicha, A. J. Ridley, and G. E. Jones. 1998. A role for Cdc42 in macrophage chemotaxis. J. Cell. Biol. 141: 1147-1157.
46. Honing, H., T. K. van den Berg, S. M. van der Pol, C. D. Dijkstra, R. A. van der Kammen, J. G. Collard, and H. E. de Vries. 2004. RhoA activation promotes transendothelial migration of monocytes via ROCK. J. Leukocyte Biol. 75: 523-528.
47. Segain, J. P., D. Raingeard de la Bletiere, V. Sauzeau, A. Bourreille, G. Hilaret, C. Cario-Toumaniantz, P. Pacaud, J. P. Galmiche, and G. Loirand. 2003. Rho kinase blockade prevents inflammation via nuclear factor κB inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology 124: 1180-1187.
48. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894-897.
49. Gu, L., Y. Okada, S. K. Clinton, C. Gerard, G. K. Sukhova, P. Libby, and B. J. Rollins. 1998. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell. 2: 275-281.
50. Bjorkbacka, H., V. V. Kunjathoor, K. J. Moore, S. Koehn, C. M. Ordija, M. A. Lee, T. Means, K. Halmen, A. D. Luster, D. T. Golenbock, and M. W. Freeman. 2004. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med. 10: 416-421.
51. Grimshaw, M. J., J. L. Wilson, and F. R. Balkwill. 2002. Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur. J. Immunol. 32: 2393-2400.
52. Funakoshi, Y., T. Ichiki, H. Shimokawa, K. Egashira, K. Takeda, K. Kaibuchi, M. Takeya, T. Yoshimura, and A. Takeshita. 2001. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 38: 100-104.
53. Mallat, Z., A. Gojova, V. Sauzeau, V. Brun, J. S. Silvestre, B. Esposito, R. Merval, H. Groux, G. Loirand, and A. Tedgui. 2003. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ. Res. 93: 884-888.